



NEWS RELEASE

NeuroVive Admitted to Trading on NASDAQ OMX Stockholm

Note: This is an English version of a press release communicated by NeuroVive 2013-03-22.

Lund (Sweden) – March 25, 2013, NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th.

The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Brönnegård, CEO of NeuroVive Pharmaceutical said: "Our move to NASDAQ OMX Stockholm is an important step forward in the growth and development of our company. Through this listing NeuroVive will gain access to a broader and deeper pool of investors that will be vital as we look to finance our strategy which is designed to maximize shareholder value from our leading position in mitochondrial medicine."

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB (www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's products are based on the cyclophilin inhibitor, cyclosporine, and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following cardiac stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.

NeuroVive's shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts

NeuroVive Pharmaceutical: Mikael Brönnegård

Email: info@neurovive.com

Phone No: +46 (0) 70 299 62 64

Citigate Dewe Rogerson: Nina Enegren / David Dible

Email: nina.enegren@citigatedr.co.uk

Phone No: +44 207 282 1050